Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Heikki Ilmavirta"'
Autor:
Heikki Ilmavirta, Jukka Ollgren, Kati Räisänen, Tuure Kinnunen, Antti Juhani Hakanen, Kaisu Rantakokko-Jalava, Jari Jalava, Outi Lyytikäinen
Publikováno v:
Antimicrobial Resistance and Infection Control, Vol 13, Iss 1, Pp 1-10 (2024)
Abstract Background Before the COVID-19 pandemic there has been a constant increase in antimicrobial resistance (AMR) of Escherichia coli, the most common cause of urinary tract infections and bloodstream infections. The aim of this study was to inve
Externí odkaz:
https://doaj.org/article/57f4199a949d470bb26aa09ccbfe28ec
Autor:
Kati, Räisänen, Irma, Koivula, Heikki, Ilmavirta, Santeri, Puranen, Teemu, Kallonen, Outi, Lyytikäinen, Jari, Jalava
Publikováno v:
Eurosurveillance
In December 2018, a ceftazidime-avibactam (CAZ-AVI)-resistant KPC-2-producing Klebsiella pneumoniae strain was isolated in Finland. CAZ-AVI resistance was observed 34 days after CAZ-AVI treatment in a trauma patient transferred from a hospital in Gre
Autor:
Irma Koivula, Outi Lyytikäinen, Santeri Puranen, Heikki Ilmavirta, Kati Räisänen, Jari Jalava, Teemu Kallonen
Ceftazidime-avibactam (CAZ-AVI) is a promising novel β-lactam-β-lactamase inhibitor combination with activity against multidrug-resistant (MDR) Enterobacteriaceae for which there are limited treatment options, e.g. those producing Klebsiella pneumo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1e89ea564ec37ddad842e723a0e6e249
https://aaltodoc.aalto.fi/handle/123456789/39397
https://aaltodoc.aalto.fi/handle/123456789/39397